McMMAF
Modify Date: 2025-08-26 11:13:12
McMMAF structure
|
Common Name | McMMAF | ||
|---|---|---|---|---|
| CAS Number | 863971-19-1 | Molecular Weight | 925.161 | |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 1052.0±65.0 °C at 760 mmHg | |
| Molecular Formula | C49H76N6O11 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 590.1±34.3 °C | |
Use of McMMAFMc-MMAF is a protective group-conjugated MMAF. MMAF is a more potent drug than Monomethyl auristatin E (MMAE), but is charged and relatively membrane-impermeable, is a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate.Target:MMAF is a new auristatin derivative with a charged C-terminal phenylalanine that attenuates its cytotoxic activity compared to its uncharged counterpart, Monomethyl auristatin E (MMAE). Because of MMAF is highly toxic, it cannot be used as a drug itself. MMAF induces potent antitumor effects when conjugated via protease cleavable linkers to a monoclonal antibody targeting internalizing, tumor-specific cell surface antigens. The linker to the monoclonal antibody is stable in extracellular fluid, but is cleaved by cathepsin once the conjugate has entered a tumor cell, thus activating the anti-mitotic mechanism. |
| Name | Mafodotin |
|---|---|
| Synonym | More Synonyms |
| Description | Mc-MMAF is a protective group-conjugated MMAF. MMAF is a more potent drug than Monomethyl auristatin E (MMAE), but is charged and relatively membrane-impermeable, is a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate.Target:MMAF is a new auristatin derivative with a charged C-terminal phenylalanine that attenuates its cytotoxic activity compared to its uncharged counterpart, Monomethyl auristatin E (MMAE). Because of MMAF is highly toxic, it cannot be used as a drug itself. MMAF induces potent antitumor effects when conjugated via protease cleavable linkers to a monoclonal antibody targeting internalizing, tumor-specific cell surface antigens. The linker to the monoclonal antibody is stable in extracellular fluid, but is cleaved by cathepsin once the conjugate has entered a tumor cell, thus activating the anti-mitotic mechanism. |
|---|---|
| Related Catalog | |
| References |
[2]. Jianmin Fang, et al. Anti-her2 antibody and conjugate thereof. US 20160304621 A1. |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 1052.0±65.0 °C at 760 mmHg |
| Molecular Formula | C49H76N6O11 |
| Molecular Weight | 925.161 |
| Flash Point | 590.1±34.3 °C |
| Exact Mass | 924.557190 |
| LogP | 5.04 |
| Vapour Pressure | 0.0±0.3 mmHg at 25°C |
| Index of Refraction | 1.538 |
| Storage condition | 2-8℃ |
| Mafodotin |
| N-[6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-N-methyl-L-valyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(1S)-1-carboxy-2-phenylethyl]amino}-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl}-3-methoxy-5-methyl-1-oxo-4-heptanyl]-N-methyl-L-valinamide |
| L-Valinamide, N-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-N-methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl- |
| McMMAF |